Direct Selling Acquisition Corp. operates as a blank check company. The company is headquartered in Plano, Texas. The company went IPO on 2021-09-24. The firm is formed for the purpose of entering a merger, share exchange, asset acquisition, share purchase, recapitalization, reorganization, or similar business combination with one or more businesses or entities. The firm has not selected any specific business combination target and has not, nor has anyone on its behalf, initiated any substantive discussions, directly or indirectly, with any business combination target. The company intends to focus its search on domestically based businesses within the direct selling industry. The firm has not commenced any operations nor generated any revenues.
Direct Selling Acquisition Corp 的收入按细分市场或地理位置如何划分?
Silexion Therapeutics Corp 最大收入来源是 Banking and Related Activities,在最近的收益报告中收入为 18,735,887。就地区而言, United States 是 Silexion Therapeutics Corp 的主要市场,收入为 18,735,887。